{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:55:13Z","timestamp":1787028913932,"version":"build-2736575974"},"reference-count":60,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T00:00:00Z","timestamp":1710374400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Cystic fibrosis-related diabetes (CFRD) is the most common comorbidity in patients with cystic fibrosis (CF). CFRD has been correlated with important clinical outcomes, including poor nutrition, reduced pulmonary function, and earlier mortality. However, clinical decline due to abnormalities of blood glucose (dysglycemia) begins early in CF, before the diagnosis of CFRD by the gold-standard oral glucose tolerance test (OGTT). Continuous glucose monitoring (CGM) has been validated in patients with CF and has been recognized as a valuable tool in detecting early glucose abnormalities in patients with CF. Several CGM parameters have been used to predict CFRD in some but not all studies, and there is no consensus regarding CGM use for diagnostic purposes. Thus, it remains a complementary test to OGTT in CFRD diagnosis. The aim of this review is to provide an update on the pathophysiological mechanisms of CFRD, recent advances in the use of CGM for CFRD screening, and the association between CGM measures and CF-related clinical outcomes.<\/jats:p>","DOI":"10.3390\/medicina60030477","type":"journal-article","created":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T05:43:08Z","timestamp":1710394988000},"page":"477","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["The Role of Continuous Glucose Monitoring in Detecting Early Dysglycemia and Clinical Outcomes in Patients with Cystic Fibrosis"],"prefix":"10.3390","volume":"60","author":[{"given":"Lora Stanka","family":"Kirigin Bilo\u0161","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Diabetes and Metabolic Diseases \u201cMladen Sekso\u201d, University Hospital Centre \u201cSestre Milosrdnice\u201d, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9076-9870","authenticated-orcid":false,"given":"Velimir","family":"Altabas","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetes and Metabolic Diseases \u201cMladen Sekso\u201d, University Hospital Centre \u201cSestre Milosrdnice\u201d, 10000 Zagreb, Croatia"},{"name":"School of Medicine, University of Zagreb, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1522-3325","authenticated-orcid":false,"given":"Andrea","family":"Vuki\u0107 Dugac","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Zagreb, 10000 Zagreb, Croatia"},{"name":"University Hospital Centre Zagreb, Cystic Fibrosis Centre for Pediatrics and Adults, 10000 Zagreb, Croatia"},{"name":"Clinic for respiratory diseases \u201cJordanovac\u201d, University Hospital Centre Zagreb, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7242-8407","authenticated-orcid":false,"given":"Maja","family":"Bareti\u0107","sequence":"additional","affiliation":[{"name":"University Hospital Centre Zagreb, Cystic Fibrosis Centre for Pediatrics and Adults, 10000 Zagreb, Croatia"},{"name":"Internal clinic, Department of Endocrinology and Diabetology, University Hospital Centre Zagreb, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,3,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1016\/S0140-6736(09)60327-5","article-title":"Cystic fibrosis","volume":"373","author":"Freedman","year":"2009","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/apa.15155","article-title":"Cystic fibrosis in the year 2020: A disease with a new face","volume":"109","year":"2020","journal-title":"Acta Paediatr."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"R35","DOI":"10.1530\/JOE-18-0468","article-title":"Survival in a bad neighborhood: Pancreatic islets in cystic fibrosis","volume":"241","author":"Norris","year":"2019","journal-title":"J. Endocrinol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"677","DOI":"10.2337\/db22-0949","article-title":"Cystic Fibrosis-Related Diabetes Workshop: Research Priorities Spanning Disease Pathophysiology, Diagnosis, and Outcomes","volume":"72","author":"Putman","year":"2023","journal-title":"Diabetes"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.2337\/dc10-1279","article-title":"Epidemiology, pathophysiology, and prognostic implications of cystic fibrosis-related diabetes: A technical review","volume":"33","author":"Moran","year":"2010","journal-title":"Diabetes Care"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"102899","DOI":"10.1016\/j.dsx.2023.102899","article-title":"Advances in cystic fibrosis-related diabetes: Current status and future directions","volume":"17","author":"Lurquin","year":"2023","journal-title":"Diabetes Metab. Syndr."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1179551419851770","DOI":"10.1177\/1179551419851770","article-title":"Cystic Fibrosis-Related Diabetes: Pathophysiology and Therapeutic Challenges","volume":"12","author":"Kelsey","year":"2019","journal-title":"Clin. Med. Insights Endocrinol. Diabetes"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"659728","DOI":"10.3389\/fped.2021.659728","article-title":"Continuous Glucose Monitoring as a Valuable Tool in the Early Detection of Diabetes Related to Cystic Fibrosis","volume":"9","author":"Gojsina","year":"2021","journal-title":"Front. Pediatr."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.cmet.2017.06.010","article-title":"Insulin Regulation of Proteostasis and Clinical Implications","volume":"26","author":"James","year":"2017","journal-title":"Cell Metab."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jcf.2006.03.009","article-title":"Airway glucose concentrations and effect on growth of respiratory pathogens in cystic fibrosis","volume":"6","author":"Brennan","year":"2007","journal-title":"J. Cyst. Fibros."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3389\/fendo.2018.00020","article-title":"Cystic Fibrosis-Related Diabetes","volume":"9","author":"Kayani","year":"2018","journal-title":"Front. Endocrinol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Anton-P\u0103duraru, D.-T., Murgu, A.M., Donos, M.A., Trofin, F., Azoic\u0103i, A.N., Popovici, P., Stana, A.B., Gheorghiescu, I., and Trandafir, L.M. (2023). An Update in Cystic Fibrosis-Related Diabetes in Children and Adolescents. Children, 10.","DOI":"10.3390\/children10121879"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"673539","DOI":"10.3389\/fendo.2021.673539","article-title":"Diabetes and Prediabetes in Children with Cystic Fibrosis: A Systematic Review of the Literature and Recommendations of the Italian Society for Pediatric Endocrinology and Diabetes (ISPED)","volume":"12","author":"Mozzillo","year":"2021","journal-title":"Front. Endocrinol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/pedi.12158","article-title":"Why is insulin pump treatment rarely used in adolescents and young adults with cystic fibrosis-related diabetes?","volume":"16","author":"Scheuing","year":"2015","journal-title":"Pediatr. Diabetes"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.jcf.2019.08.003","article-title":"Cystic fibrosis related diabetes: Medical management","volume":"18","author":"Ode","year":"2019","journal-title":"J. Cyst. Fibros."},{"key":"ref_16","unstructured":"Doan, L.V., and Madison, L.D. (2023). StatPearls, StatPearls Publishing."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2337\/dc09-1215","article-title":"Diabetes as a Determinant of Mortality in Cystic Fibrosis","volume":"33","author":"Chamnan","year":"2010","journal-title":"Diabetes Care"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jpeds.2004.12.039","article-title":"Epidemiology of cystic fibrosis-related diabetes","volume":"146","author":"Marshall","year":"2005","journal-title":"J. Pediatr."},{"key":"ref_19","first-page":"100278","article-title":"Cystic fibrosis related diabetes (CFRD) prognosis","volume":"26","author":"Sandouk","year":"2021","journal-title":"J. Clin. Transl. Endocrinol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.2337\/dc10-1768","article-title":"Clinical Care Guidelines for Cystic Fibrosis\u2013Related Diabetes","volume":"33","author":"Moran","year":"2010","journal-title":"Diabetes Care"},{"key":"ref_21","unstructured":"(2021, March 10). Cystic Fibrosis Foundation Patient Registry: Annual. Available online: https:\/\/scholar.google.com\/scholar_lookup?title=Annual%20data%20report%20bethesda%2C%20Maryland%202022%20cystic%20fibrosis%20foundationle&publication_year=2021&author=Cystic%20Fibrosis%20Foundation%20Patient%20Registry."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e1444","DOI":"10.1210\/clinem\/dgab857","article-title":"Continuous Glucose Monitoring and HbA1c in Cystic Fibrosis: Clinical Correlations and Implications for CFRD Diagnosis","volume":"107","author":"Scully","year":"2022","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/j.1464-5491.2004.01219.x","article-title":"Conventional measures underestimate glycaemia in cystic fibrosis patients","volume":"21","author":"Dobson","year":"2004","journal-title":"Diabet. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.jcf.2017.12.004","article-title":"Quantifying fluctuation in glucose levels to identify early changes in glucose homeostasis in cystic fibrosis","volume":"17","author":"Brugha","year":"2017","journal-title":"J. Cyst. Fibros."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.jcf.2013.11.005","article-title":"Early assessment of glucose abnormalities during continuous glucose monitoring associated with lung function impairment in cystic fibrosis patients","volume":"13","author":"Leclercq","year":"2014","journal-title":"J. Cyst. Fibros."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.2337\/dc08-1925","article-title":"Validation of continuous glucose monitoring in children and adolescents with cystic fibrosis: A prospective cohort study","volume":"32","author":"Hindmarsh","year":"2009","journal-title":"Diabetes Care"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.jcf.2019.08.025","article-title":"Continuous glucose monitoring in cystic fibrosis \u00c0 A practical guide","volume":"18","author":"Chan","year":"2019","journal-title":"J. Cyst. Fibros."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e2221","DOI":"10.1210\/clinem\/dgac034","article-title":"Complications of Diabetes and Metrics of Glycemic Management Derived From Continuous Glucose Monitoring","volume":"107","author":"Yapanis","year":"2022","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.jcf.2018.03.008","article-title":"Continuous glucose monitoring abnormalities in cystic fibrosis youth correlate with pulmonary function decline","volume":"17","author":"Chan","year":"2018","journal-title":"J. Cyst. Fibros."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.jcf.2019.03.010","article-title":"Early glucose abnormalities are associated with pulmonary inflammation in young children with cystic fibrosis","volume":"18","author":"Prentice","year":"2019","journal-title":"J. Cyst. Fibros."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.2337\/dc23-S002","article-title":"2. Classification and Diagnosis of Diabetes: Standards of Care in Diabetes-2023","volume":"46","author":"ElSayed","year":"2023","journal-title":"Diabetes Care"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/S0022-3476(05)80032-0","article-title":"Pancreatic endocrine function in cystic fibrosis","volume":"118","author":"Moran","year":"1991","journal-title":"J. Pediatr."},{"key":"ref_33","first-page":"90A","article-title":"Accelerated Red Blood Cell Turnover Can Invalidate the Use of Hemoglobin A1c as a Diagnostic Test for Cystic Fibrosis Related Diabetes","volume":"45","author":"Hardin","year":"1999","journal-title":"Pediatr. Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jcf.2016.02.012","article-title":"Hypoglycaemia in cystic fibrosis in the absence of diabetes: A systematic review","volume":"15","author":"Armaghanian","year":"2016","journal-title":"J. Cyst. Fibros."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e20210307","DOI":"10.36416\/1806-3756\/e20210307","article-title":"Can continuous glucose monitoring predict cystic fibrosis-related diabetes and worse clinical outcome?","volume":"48","author":"Zorron","year":"2022","journal-title":"J. Bras. Pneumol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.jcf.2019.08.016","article-title":"Cystic fibrosis related diabetes: Pathophysiology, screening and diagnosis","volume":"18","author":"Granados","year":"2019","journal-title":"J. Cyst. Fibros."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"702823","DOI":"10.3389\/fendo.2021.702823","article-title":"The Potential Causes of Cystic Fibrosis-Related Diabetes","volume":"12","author":"Coderre","year":"2021","journal-title":"Front. Endocrinol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jcf.2018.02.006","article-title":"ECFS best practice guidelines: The 2018 revision","volume":"17","author":"Castellani","year":"2018","journal-title":"J. Cyst. Fibros."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e548","DOI":"10.1210\/clinem\/dgab692","article-title":"The Relationship Between Continuous Glucose Monitoring and OGTT in Youth and Young Adults with Cystic Fibrosis","volume":"107","author":"Chan","year":"2022","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_40","first-page":"100305","article-title":"Comparison of continuous glucose monitoring to reference standard oral glucose tolerance test for the detection of dysglycemia in cystic Fibrosis: A systematic review","volume":"30","author":"Kumar","year":"2022","journal-title":"J. Clin. Transl. Endocrinol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.2337\/dc10-2289","article-title":"Hyperglycemia and death in cystic fibrosis-related diabetes","volume":"34","author":"Adler","year":"2011","journal-title":"Diabetes Care"},{"key":"ref_42","first-page":"1","article-title":"Glucose >200 mg\/dL during Continuous Glucose Monitoring Identifies Adult Patients at Risk for Development of Cystic Fibrosis Related Diabetes","volume":"2016","author":"Janssen","year":"2016","journal-title":"J. Diabetes Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1530\/EJE-09-1020","article-title":"Abnormal glucose tolerance in children with cystic fibrosis: The predictive role of continuous glucose monitoring system","volume":"162","author":"Schiaffini","year":"2010","journal-title":"Eur. J. Endocrinol."},{"key":"ref_44","unstructured":"Rabasa-Lhoret, R., Kessler, L., and Durieu, I. (2024, January 14). Identification of Dysglycemia with Continuous Glucose Monitoring to Assess Clinical Evolution in Cystic Fibrosis. ClinicalTrials.gov Identifier: NCT05099939, Available online: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05099939?term=ProspeC-F&draw=2&rank=1."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1210\/clinem\/dgaa932","article-title":"Glucose Tolerance Stages in Cystic Fibrosis Are Identified by a Unique Pattern of Defects of Beta-Cell Function","volume":"106","author":"Piona","year":"2021","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_46","first-page":"100323","article-title":"Reproducibility of in-home CFRD screening using continuous glucose monitoring and mixed meal tolerance test","volume":"33","author":"Kutney","year":"2023","journal-title":"J. Clin. Transl. Endocrinol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1515\/CCLM.2007.505","article-title":"Reproducibility of impaired glucose tolerance (IGT) and impaired fasting glucose (IFG) classification: A systematic review","volume":"45","author":"Balion","year":"2007","journal-title":"Clin. Chem. Lab. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.jcf.2020.02.009","article-title":"Glucose abnormalities detected by continuous glucose monitoring are common in young children with Cystic Fibrosis","volume":"19","author":"Prentice","year":"2020","journal-title":"J. Cyst. Fibros."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.diabet.2008.05.010","article-title":"No relationship between mean plasma glucose and glycated haemoglobin in patients with cystic fibrosis-related diabetes","volume":"34","author":"Godbout","year":"2008","journal-title":"Diabetes Metab."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Izs\u00e1k, V.D., So\u00f3s, A., Szak\u00e1cs, Z., Hegyi, P., Juh\u00e1sz, M.F., Varannai, O., Martonosi, R., F\u00f6ldi, M., Kozma, A., and Vajda, Z. (2021). Screening methods for diagnosing cystic fibrosis-related diabetes: A network meta-analysis of diagnostic accuracy studies. Biomolecules, 11.","DOI":"10.3390\/biom11040520"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.2337\/dc17-2419","article-title":"Hemoglobin A1c Accurately Predicts Continuous Glucose Monitoring-Derived Average Glucose in Youth and Young Adults with Cystic Fibrosis","volume":"41","author":"Chan","year":"2018","journal-title":"Diabetes Care"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Scheuing, N., Holl, R.W., Dockter, G., Hermann, J.M., Junge, S., Koerner-Rettberg, C., Naehrlich, L., Smaczny, C., Staab, D., and Thalhammer, G. (2014). High variability in oral glucose tolerance among 1,128 patients with cystic fibrosis: A multicenter screening study. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0112578"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"292","DOI":"10.2337\/dc10-1604","article-title":"Elevation of 1-Hour Plasma Glucose during Oral Glucose Tolerance Testing Is Associated with Worse Pulmonary Function in Cystic Fibrosis","volume":"34","author":"Brodsky","year":"2011","journal-title":"Diabetes Care"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.jcf.2019.05.005","article-title":"Peak OGTT glucose is associated with lower lung function in young children with cystic fibrosis","volume":"19","author":"Prentice","year":"2010","journal-title":"J. Cyst. Fibros."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.jcf.2021.01.002","article-title":"Abnormal glucose tolerance and lung function in children with cystic fibrosis. Comparing oral glucose tolerance test and continuous glucose monitoring","volume":"20","author":"Elidottir","year":"2021","journal-title":"J. Cyst. Fibros."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.jcf.2018.05.005","article-title":"Continuous glucose monitoring guided insulin therapy is associated with improved clinical outcomes in cystic fibrosis-related diabetes","volume":"17","author":"Frost","year":"2018","journal-title":"J. Cyst. Fibros."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2337\/dc09-1492","article-title":"Early glucose abnormalities in cystic fibrosis are preceded by poor weight gain","volume":"33","author":"Hameed","year":"2010","journal-title":"Diabetes Care"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jcf.2022.08.016","article-title":"Glycemic indices at night measured by CGM are predictive for a lower pulmonary function in adults but not in children with cystic fibrosis","volume":"22","author":"Declercq","year":"2023","journal-title":"J. Cyst. Fibros."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1136\/adc.2010.204636","article-title":"Once daily insulin detemir in cystic fibrosis with insulin deficiency","volume":"97","author":"Hameed","year":"2012","journal-title":"Arch. Dis. Child"},{"key":"ref_60","unstructured":"Verge, C. (2024, January 14). Cystic Fibrosis\u2013Insulin Deficiency, Early Action. ClinicalTrials.gov Identifier: NCT01100892, Available online: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT01100892."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/60\/3\/477\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:13:17Z","timestamp":1760105597000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/60\/3\/477"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,14]]},"references-count":60,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["medicina60030477"],"URL":"https:\/\/doi.org\/10.3390\/medicina60030477","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,14]]}}}